The estimated Net Worth of Jeffrey W Dunn is at least 17.5 百万$ dollars as of 16 August 2024. Jeffrey Dunn owns over 1,580 units of SI-BONE Inc stock worth over 380,197$ and over the last 6 years Jeffrey sold SIBN stock worth over 17,124,016$.
Jeffrey has made over 62 trades of the SI-BONE Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Jeffrey sold 1,580 units of SIBN stock worth 21,867$ on 16 August 2024.
The largest trade Jeffrey's ever made was exercising 272,753 units of SI-BONE Inc stock on 9 May 2023 worth over 932,815$. On average, Jeffrey trades about 16,345 units every 27 days since 2019. As of 16 August 2024 Jeffrey still owns at least 25,212 units of SI-BONE Inc stock.
You can see the complete history of Jeffrey Dunn stock trades at the bottom of the page.
Jeffrey's mailing address filed with the SEC is C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA, CA, 95050.
Over the last 6 years, insiders at SI-BONE Inc have traded over 114,943,926$ worth of SI-BONE Inc stock and bought 1,250,000 units worth 18,750,000$ . The most active insiders traders include David P Bonita、Advisors Llc Orbi Med Capit...、John Gordon Freund. On average, SI-BONE Inc executives and independent directors trade stock every 8 days with the average trade being worth of 401,535$. The most recent stock trade was executed by Anshul Maheshwari on 3 September 2024, trading 1,414 units of SIBN stock currently worth 23,119$.
si-bone® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (si) joint. si-bone developed an innovative, patented implant to fuse the si joint. the ifuse implant system® provides a less invasive alternative to traditional sacroiliac (si) joint fusion surgery and has been used in over 25,000 procedures to date. the company is managed by an experienced team of executives from kyphon, medtronic, inbone, saint francis and several start up orthopedic and spine companies. the ifuse implant system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. this includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. there are potential risks associated with the ifuse implant system. it may not be appropriate for al
SI-BONE Inc executives and other stock owners filed with the SEC include: